Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

Company Growth (employees)
Type
Private
HQ
Utrecht, NL
Founded
2003
Size (employees)
69 (est)+2%
Website
merus.nl
Merus was founded in 2003 and is headquartered in Utrecht, NL

Key People/Management at Merus

Ton Logtenberg

Ton Logtenberg

CEO
John J. Crowley

John J. Crowley

Chief Financial Officer
John de Kruif

John de Kruif

Chief Technology Officer
L. Andres Sirulnik

L. Andres Sirulnik

Chief Medical Officer
Lex Bakker

Lex Bakker

Chief Development Officer
Hui Liu

Hui Liu

Chief Business Officer
Mark Throsby

Mark Throsby

Chief Scientific Office

Merus Office Locations

Merus has an office in Utrecht
Utrecht, NL (HQ)
62 Yalelaan
Utrecht, NL (HQ)
H.R. Kruytgebouw 8 Padualaan

Merus Financials and Metrics

Summary Metrics

Merus's latest funding round in April 2015 was reported to be $79.1 m. In total, Merus has raised $149.3 m

Traffic Overview of Merus

Merus Company Life and Culture

You may also be interested in